WNT5A is a putative epi‐driver of prostate cancer metastasis to the bone
Cancer Medicine · 2024-08 · 13 (16)
DOI: 10.1002/cam4.70122 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 20.08.2024. Verfasst von Emma J Wilkinson und 6 weiteren Autor:innen. Beteiligte Einrichtung: Tasmanian School of Medicine, University of Tasmania, Hobart, Tasmania, Australia. Hauptthemen laut MEDLINE: Wnt-5a Protein, Prostatic Neoplasms, Bone Neoplasms, DNA Methylation. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Andree Greenwood Secondary Breast Cancer Fund, Cancer Council Tasmania, Select Foundation Cancer Research Fellowship.
Abstract (Originalsprache)
Background
Current diagnostic tools are unable to distinguish low‐grade indolent prostate cancer (PrCa) from that with a propensity to become metastatic and/or lethal. Recent evidence suggests that reprogramming of the transcriptome may drive the metastatic phenotype, and that this reprogramming is controlled, at least in part, by epigenetic changes to the DNA of cancer cells, including methylation. These changes, referred to as ‘epigenetic drivers,’ have previously been associated with cancer cell survival.
Methods
Here, using Illumina Methylation EPIC array data of paired primary PrCa and metastatic bone samples, we identified WNT5A as a putative epi‐driver of PrCa metastasis to the bone, which was further validated in vitro.
Results
Significantly higher WNT5A methylation was observed in primary PrCa samples and 22Rv1 cells compared to metastatic bone samples and PC‐3 cells. This higher methylation was associated with significantly lower WNT5A gene expression.
Conclusion
Given the limited effective therapies available for metastatic cancer sufferers, particularly those whose disease has metastasised to the bone, WNT5A presents as a potential putative target for therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Tasmanian School of Medicine, University of Tasmania, Hobart, Tasmania, Australia.
- Menzies Institute for Medical Research, University of Tasmania, Hobart, Tasmania, Australia.
- Anatomical Pathology, Royal Hobart Hospital, Hobart, Tasmania, Australia.
- Diagnostic Services, Sonic Healthcare, Hobart, Tasmania, Australia.
- Icon Cancer Centre, Hobart, Tasmania, Australia.
- Oncology and Haematology, Royal Hobart Hospital, Hobart, Tasmania, Australia.
ORCID-Profile: Kelsie Raspin, Joanne L Dickinson
Förderung
- Andree Greenwood Secondary Breast Cancer Fund
- Cancer Council Tasmania
- Select Foundation Cancer Research Fellowship
- Hobart Police Charity Trust
- Royal Hobart Hospital Research Foundation
- Cancer Council Tasmania Joy & Robert Coghlan/College of Health and Medicine Postdoctoral Research Fellowship
- Cuthbertson Brothers Elite Postgraduate Scholarship
- Australian Research Council Future Fellowship
Zitieren
APA
Wilkinson, E. J., Raspin, K., Malley, R. C., Donovan, S., Nott, L. M., Holloway, A. F., & Dickinson, J. L. (2024). WNT5A is a putative epi‐driver of prostate cancer metastasis to the bone. Cancer Medicine, 13(16). https://doi.org/10.1002/cam4.70122
Vancouver
Wilkinson EJ, Raspin K, Malley RC, Donovan S, Nott LM, Holloway AF, et al. WNT5A is a putative epi‐driver of prostate cancer metastasis to the bone. Cancer Medicine. 2024;13(16). doi:10.1002/cam4.70122
BibTeX
@article{Wilkinson2024,
author = {Wilkinson, Emma J and Raspin, Kelsie and Malley, Roslyn C and Donovan, Shaun and Nott, Louise M and Holloway, Adele F and Dickinson, Joanne L},
title = {WNT5A is a putative epi‐driver of prostate cancer metastasis to the bone},
journal = {Cancer Medicine},
year = {2024},
volume = {13},
number = {16},
doi = {10.1002/cam4.70122}
}
EUVIMED